文献速递骨质疏松与代谢性骨病

钙同位素比值δ44/42Ca反映肾功能与钙排泄,但不反映骨密度或骨转换:一项横断面研究

Calcium isotope ratio (δ44/42Ca) reflects kidney function and calcium excretion but not bone mineral density or bone turnover: a cross-sectional study.
PubMed 文献 · Osteoporos Int · 2026-04-11

该横断面研究纳入301例患者(43例对照),分析血清和尿δ44/42Ca与骨密度、骨转换标志物等的关系。δ44/42Ca与尿钙排泄强相关,但与骨密度、骨折状态及骨转换标志物无关,且受年龄、肾功能和钙摄入影响,提示其临床诊断价值有限。

要点

  • δ44/42Ca与尿钙排泄强相关,但与骨密度和骨折状态无关。
  • 年龄、肾功能和钙摄入显著影响δ44/42Ca,解读时需考虑。
  • δ44/42Ca不能区分骨质疏松、骨量减少与健康对照,临床用途有限。

核心结论

  • δ44/42Ca反映钙代谢某些方面如营养钙供应,但在真实临床环境中未能预测骨折或区分骨质疏松与健康对照或骨量减少,临床用途有限。
  • δ44/42Ca不能替代骨密度或实验室检查等既定骨诊断方法。

研究设计与样本

  • 横断面研究,纳入301例患者(43例对照),分析血清和尿δ44/42Ca与骨密度及治疗参数。

主要发现

  • 年龄、肾功能和钙摄入显著影响δ44/42Ca。
  • δ44/42Ca与尿钙排泄强相关(血清:r²=0.55,尿:r²=0.20;p<0.0001),但与骨转换标志物或骨密度无关。
  • 较高β-CTX与低δ44/42Ca水平相关(p<0.05)。
  • 骨合成代谢治疗增加δ44/42Ca(p<0.05),而抗骨吸收治疗无影响。
  • 按骨折或骨密度分层未见δ44/42Ca差异,但年龄校正后δ44/42Ca分层显示高于阈值者尿钙和PTH更高(均p<0.0001)。

关键数值与推荐

  • δ44/42Ca与尿钙排泄相关:血清r²=0.55,尿r²=0.20,p<0.0001。
  • 较高β-CTX与低δ44/42Ca水平相关,p<0.05。
  • 骨合成代谢治疗增加δ44/42Ca,p<0.05。
  • 年龄校正后δ44/42Ca高于阈值者尿钙和PTH更高,均p<0.0001。

临床怎么用

  • δ44/42Ca不能替代骨密度或实验室检查用于骨质疏松诊断。
  • 解读δ44/42Ca时需考虑年龄、肾功能和钙摄入的影响。

局限性

  • δ44/42Ca在真实临床环境中未能预测骨折或区分骨质疏松与健康对照或骨量减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Calcium isotope fractionation (δ⁴⁴/⁴²Ca) was evaluated as a biomarker of bone metabolism in 301 patients. δ⁴⁴/⁴²Ca correlated with urinary calcium excretion but not with bone mineral density or fracture status. Age, kidney function, and calcium intake influenced results, limiting its diagnostic utility for osteoporosis in clinical practice. Data on Calcium isotope fractions (δ44/42Ca) in isolated bone diseases are limited. Previously proposed as a diagnostic marker in metabolic bone disorders, we now extend our findings from monogenic bone diseases to patients with osteoporosis and osteopenia. METHODS: In 301 patients (43 controls), serum and urine δ44/42Ca were analyzed alongside bone (such as bone density) and treatment parameters. RESULTS: Age, kidney function, and calcium intake significantly affected δ44/42Ca and must be considered in interpretation. δ44/42Ca correlated strongly with urinary calcium excretion (serum: r²=0.55, urine: r²=0.20; p<0.0001) but not with bone turnover markers or BMD. Higher β-CTX were associated with low δ44/42Ca levels (p<0.05). Osteoanabolic therapy increased δ44/42Ca (p<0.05), whereas antiresorptive treatment had no effect. No differences in δ44/42Ca appeared by fracture or BMD stratification, but age-adjusted δ44/42Ca stratification showed higher urinary calcium and PTH (both p<0.0001) in individuals above the threshold, a pattern consistent with neutral or positive bone mineral balance. CONCLUSION: While δ44/42Ca reflects aspects of calcium metabolism, such as nutritional calcium supply, in this real-world setting, it failed to predict fractures or distinguish osteoporosis from healthy controls or osteopenia and vice versa, indicating limited clinical use. Thus, although δ44/42Ca is a parameter of interest for calcium metabolism, it does not substitute established bone diagnostics such as BMD or laboratory assessments. Future studies are needed to determine if and how δ44/42Ca can contribute to individualized diagnostics and treatment monitoring in bone disease.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. von Brackel FN, Bartosik M, Munzinger R, et al. Calcium isotope ratio (δ44/42Ca) reflects kidney function and calcium excretion but not bone mineral density or bone turnover: a cross-sectional study. Osteoporos Int. 2026. PMID: 41964678. doi:10.1007/s00198-026-07935-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。